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Abstract
Background: Previous animal studies have shown that Curcuma (C.) longa lowers plasma glucose. C. longa may
thus be a promising ingredient in functional foods aimed at preventing type 2 diabetes. The purpose of the study
is to study the effect of C. longa on postprandial plasma glucose, insulin levels and glycemic index (GI) in healthy
subjects.
Methods: Fourteen healthy subjects were assessed in a crossover trial. A standard 75 g oral glucose tolerance test
(OGTT) was administered together with capsules containing a placebo or C. longa. Finger-prick capillary and
venous blood samples were collected before, and 15, 30, 45, 60, 90, and 120 min after the start of the OGTT to
measure the glucose and insulin levels, respectively.
Results: The ingestion of 6 g C. longa had no significant effect on the glucose response. The change in insulin was
significantly higher 30 min (P = 0.03) and 60 min (P = 0.041) after the OGTT including C. longa. The insulin AUCs
were also significantly higher after the ingestion of C. longa, 15 (P = 0.048), 30 (P = 0.035), 90 (P = 0.03), and 120
(P = 0.02) minutes after the OGTT.
Conclusions: The ingestion of 6 g C. longa increased postprandial serum insulin levels, but did not seem to affect
plasma glucose levels or GI, in healthy subjects. The results indicate that C. longa may have an effect on insulin secretion.
Trial registration number: NCT01029327.
Background
C. longa (turmeric) is a tropical plant that is cultivated
extensively in Asia, India, China, and other countries
with a suitable climate. C. longa, is a perennial herb,
and a member of the ginger family. It can grow up to
1 m high, and has oblong, tufted leaves. The yellow
spice is made from the rhizomes (roots), which are
boiled, dried, and then ground [1,2] The active compo-
nent in turmeric is curcumin, which may constitute 2 to
8% of the spice. Curcumin is a non-water-soluble poly-
phenol that can be derived from C. longa by ethanol
extraction [2]. C. longa has traditionally been used as a
coloring agent in Asian cuisine, as well as in cheese,
butter, yogurt, and other kinds of food [3].
C. longa is used for several purposes apart from fla-
voring and coloring food. Numerous studies have shown
that curcumin has antioxidant and anti-inflammatory
properties [4]. Recent studies have also indicated that
curcumin affects cellular enzymes, and angiogenesis
[5,6]. Although curcumin has been used throughout his-
tory, especially in India and Asia, the first study on cur-
cumin and its dose-limiting toxicity was not published
until 2001, when it was reported that amounts of up to
8 g, administered per day for three months, were not
toxic to humans [7]. A long-term study on healthy sub-
ject revealed no changes in fasting plasma glucose or
lipid levels when 2.8 g turmeric was given to the sub-
jects daily for four weeks [8]. Diabetic rats given curcu-
min showed a significant reduction in renal dysfunction
and oxidative stress [9], which may indicate that curcu-
min has a protective role against diabetic nephropathy.* Correspondence: jennie.wickenberg@skane.se1Department of Medicine (JW, JH), Skåne University Hospital, Malmö,
Sweden
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Changes in lifestyle, such as increased energy intake
and decreased physical activity, are causing overweight
and obesity, leading to an epidemical increase in type 2
diabetes. It is well known that both obesity and type 2
diabetes increase inflammatory responses and cause
metabolic disorders [10]. Low glycemic index (GI) and
low glycemic load diets are associated with a reduced
risk of type 2 diabetes, which is comparable to the risk
reduction observed with a high intake of dietary fiber
and whole-grain products [11]. Dietary intervention is
thus very important in all stages of diabetes, and the
identification of dietary components that can reduce the
risk of developing diabetes, or complications associated
with diabetes, would be valuable. The effects of C. longa
on plasma glucose and insulin levels have not been stu-
died previously in humans. This study was therefore
designed to determine whether the ingestion of 6 g of
C. longa in a single meal lowered postprandial plasma
glucose and insulin levels in healthy subjects.
Methods
Fourteen healthy subjects [seven males, seven females;
(mean ± SD) age: 29 ± 1 y (range: 25 - 38 y); body mass
index: 23.9 ± 2.7 kg/m2 (range: 20.1 - 31.5 kg/m2)] were
included in this crossover study. All subjects were
recruited from the population of southern Sweden.
Those who had a history of thyroid disorders or diabetes
mellitus were excluded. The fasting plasma glucose con-
centration of each subject was checked on the day of
the examination to ensure that it was normal (≤ 7.0
mmol/L). Three subjects were smokers and three were
snuff users. The subjects were examined between eight
and 10 a.m. after a 12-h fast.
Capsules containing 560 mg lactose (Apoteket, Produk-
tion & Laboratorier, Gothenburg, Sweden) (placebo), or
170 mg lactose together with 400 mg C. longa (Svampbu-
tiken, Mediapoint AB, Västerås, Sweden), were prepared
in advance by the Malmö University Hospital Pharmacy.
Although both kinds of capsules appeared identical, it is
possible that some of the participants could discern dif-
ferences between them. The reference OGTT consisted
of 75 g/250 mL of a standard OGTT, ingested after swal-
lowing 15 placebo capsules. The test OGTT consisted of
the same amount of OGTT solution after taking 15 cap-
sules containing the C. longa. The subjects were given
250 mL of water to swallow the capsules, and were asked
to take them within five min. Extra lactose was added to
the test OGTT (5.85 g) so that the amounts of lactose in
both the reference and test OGTT, including the cap-
sules, were the same. The tests were performed in ran-
dom order at intervals of 1 week. Randomization was
performed using a table of random numbers.
Finger-prick capillary blood samples were taken for
glucose measurements, and venous blood for insulin
measurements, before, and 15, 30, 45, 60, 90, and 120
min after the consumption of the meals. Plasma glucose
concentrations were measured with the HemoCue Glu-
cose system (HemoCue AB, Ängelholm, Sweden), which
converts blood glucose to plasma equivalent glucose
concentrations by multiplying by a constant factor of
1.11 [12]. The precision of the HemoCue Glucose sys-
tem is/was better than 0.3 SD from 0 mmol/L to 22.2
mmol/L. Insulin concentrations were measured using an
immunoassay with an alkaline phosphatase conjugate
(Access Ultrasensitive Insulin, Beckman-Coulter AB,
Bromma, Sweden). The sensitivity of the insulin immu-
noassay is/was 0.03 mUnit/L (mU/L), and the intra-
assay coefficient of variation is/was below 10% in the
range 0.03 mU min/L to 300 mU/L.
All subjects gave their written informed consent. The
study was approved by the Ethics Committee of Lund
University, and performed according to the Helsinki
Declaration.
The incremental areas under the curves (AUCs) were
measured for plasma glucose, and serum insulin in each
subject (GraphPad Prism version 3.0; GraphPad Soft-
ware, San Diego, CA, USA). The AUC was calculated
above baseline. The GI and insulinemic index (GII)
were expressed as the increase in area under the glucose
curve following the test OGTT as a percentage of the
same participant’s response after the reference OGTT.
The 0-90 min and 0-120 min AUCs were used to calcu-
late the GI and GII [13,14]. All statistical calculations
were performed using SPSS for Windows software (ver-
sion 14.0, 2005). Differences in the plasma glucose
levels, insulin levels, and glycemic index were evaluated
with the Wilcoxon’s t. Values of P < 0.05 were consid-
ered statistically significant. This study, employing four-
teen healthy subjects, had an 80% power to detect a 20%
change in GI at a level of P < 0.05.
Results
Postprandial plasma glucose response
The mean fasting plasma glucose level before the refer-
ence OGTT was 5.75 ± 0.13 mmol/L and was not sta-
tistically significantly different from that before
ingestion of the test OGTT containing C. longa (5.76 ±
0.10 mmol/L). No significant differences were seen in
the glucose response at different times, or in the differ-
ences between the areas under the postprandial glucose
curves between the reference and test OGTT (Figure 1,
Table 1).
Postprandial insulin response
Ingestion of 6 g C. longa resulted in a significantly
higher serum insulin response 30 min (P = 0.048) and
60 min (P = 0.033) after the OGTT, compared with the
reference OGTT. The change in insulin level (Δ insulin)
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was also significantly different from that seen after the
reference meal 30 min (P = 0.03) and 60 min (P =
0.041) postprandially (Figure 2). The ingestion of 6 g
C. longa also resulted in a significantly higher AUC 15
min (P = 0.048), 30 min (P = 0.035), 90 min (P = 0.03)
and 120 min (P = 0.02) after the test OGTT than the
reference OGTT (Table 2).
The glycemic and insulinemic index
No significant differences were seen in GI between the
reference and test OGTT (Table 1). The ingestion of 6 g
C. longa resulted in a significantly higher GII 90 min
after the OGTT (P = 0.024), while no significant differ-
ence was seen in GII 120 min after the OGTT (Table 3).
Discussion
The aim of this study was to elucidate the effect of
C. longa on postprandial glucose and insulin levels in
healthy human subjects. The results show that the
ingestion of 6 g C. longa increased postprandial serum
insulin concentration without affecting plasma glucose
in healthy subjects. The effect of C. longa on postpran-
dial plasma glucose and insulin levels has not been stu-
died previously in humans. Curcumin is the active
component of C. longa, comprising about 2-8% of the
spice, and has been found to have potent antioxidant,
anti-inflammatory, and anti-carcinogenic properties
[5,6,11]. A decrease in blood glucose and glycosylated
hemoglobin levels has been observed when 0.08 g cur-
cumin/kg body weight or 1 g C. longa /kg body weight
was administered to diabetic rats daily for three weeks
[3]. It was also shown in the same study that curcumin
and C. longa reduced oxidative stress. Overall, the study
showed that curcumin was more effective than C. longa
in mitigating the changes typical in diabetes mellitus.
Figure 1 The mean (± SEM) incremental plasma glucose
concentration in fourteen healthy subjects after the OGTT with
placebo capsules (reference) (black diamond) or C. longa
capsules (black square). No statistically significant differences were
found between the mean plasma glucose concentrations when
evaluated with the Wilcoxon signed rank sum test.
Table 1 Postprandial plasma glucose area under the
curve (AUC) and glycemic index (GI) in healthy subjects
after the ingestion OGTT with a placebo (Reference) or
the OGTT with 6 g C. longa
Glucose AUC (mU min/L) GI (%)
Time Reference C. longa Reference C. longa
0-90 min 216.5 ± 27.4 229.6 ± 23.8 100 137.9 ± 24.8
0-120 min 253.9 ± 32.7 275.6 ± 28.3 100 135.0 ± 20.7
All values are means ± SEM, n = 14. No significant differences were found
between postprandial plasma glucose AUCs or GIs when evaluated with the
Wilcoxon signed rank sum test. U = Unit.
Figure 2 The mean (± SEM) incremental serum insulin
concentration in fourteen healthy subjects after the OGTT with
placebo capsules (reference) (black diamond) or C.
longacapsules (black square). * = Significant difference between
the responses to the reference and test OGTT when evaluated with
the Wilcoxon signed rank sum test, P < 0.05. U = Unit.
Table 2 Postprandial serum insulin area under the curve
(AUC) in healthy subjects after the ingestion of OGTT
with a placebo capsules (Reference) or the OGTT with
C. longa capsules
Insulin AUC (mU min/L)
Time Reference C. longa
0-15 min 169.2 ± 19.8 217.5 ± 37.7*
0-30 min 584.3 ± 61.2 838.1 ± 152.7*
0-45 min 1076.5 ± 111.4 1509.9 ± 252.2
0-60 min 1521.7 ± 147.3 2021.0 ± 285.9
0-90 min 2210.3 ± 215.5 2908.3 ± 353.0*
0-120 min 2749.5 ± 283.7 3570.9 ± 410.7*
All values are means ± SEM, n = 14. Significant differences in serum insulin
AUCs were evaluated with the Wilcoxon signed rank sum test. * = Significant
difference between the responses to the OGTT with and without C. longa,
P < 0.05.
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In a similar study on diabetic rats given curcumin for
two weeks (15 mg/kg and 30 mg/kg), a decrease in renal
dysfunction was observed (measured as reductions in
creatinine and urea clearance), proteinuria, together
with a decrease in oxidative stress (measured as
decreased activities of the key anti-oxidant enzymes) [9].
This indicates that curcumin may offer protection
against diabetic nephropathy. In an in vitro study in
which the effect of curcumin on human endothelial cells
was investigated, the cells were found to have an
enhanced cellular resistance to oxidative damage [15].
Obese mice with diabetes showed a significant improve-
ment in glycemic control and insulin sensitivity when
treated with 3% dietary curcumin for five weeks [10].
The improvement in glycemic status was associated
with anti-inflammatory effects. Curcumin led to a
decrease in NF-kB (nuclear factor kappa-light-chain-
enhancer of activated B cells) activity in liver tissue and
a decrease in macrophage infiltration, which can explain
the antidiabetogenic effects seen in adipose tissue fol-
lowing the ingestion of curcumin. The study also
showed that a fat-derived hormone, adiponectin,
increased dramatically. Decreased adiponectin has been
correlated with the development of insulin resistance
[16]. Recent studies show that adiponectin also has
anti-inflammatory effects on endothelial cells, thus pre-
venting atherosclerosis. Generalized inflammation and
atherosclerosis are two processes in which macrophages
plays a major roll [17,18]. Reduction of the infiltration
of macrophages into adipose tissue may be explained by
the effect of curcumin on adiponectin [10].
The animal studies described above were long-term
studies, in which various changes in the animals were
measured after a few weeks or months of administration
of curcumin or C. longa. In the present study, we mea-
sured the short-terms effect on plasma glucose and
insulin levels in healthy humans. The results of our
study show that the ingestion of 6 g C. longa increased
postprandial serum insulin concentrations without sig-
nificantly affecting plasma glucose levels, indicating that
C. longa may have an effect on insulin secretion. The
increased insulin response resulting from C. longa is
probably due to the stimulation of beta-cell function by
curcumin. This is consistent with the results of a pre-
vious in vitro study showing that curcumin enhances
insulin release in pancreatic beta-cells [19]. In healthy
subjects, glucose levels are strictly regulated, and it is
difficult to measure differences in plasma glucose levels.
This could explain why we did not see any significant
differences in plasma glucose levels.
Further investigation of the effect of C. longa on glu-
cose and insulin levels in patients with type 2 diabetes
mellitus is needed. C. longa may be an ingredient in
functional foods aimed at preventing type 2 diabetes,
but the taste of C. longa and the amount required pose
problems. It is impossible to eat 6 g of C. longa in food
because of its taste. Another issue is the bioavailability
of curcumin. It has been shown in recent studies that
curcumin has poor bioavailability because of its poor
absorption and rapid metabolism. Several studies have
indicated that the amount of curcumin in the serum
after an intake of 4-8 g is only 0.4-3.6 μM [20]. C.
Longa with its curcumin is probably a very healthy spice
in the long term, but unfortunately it has a very poor
bioavailability and it cannot be ingested on its own.
Conclusions
The present study shows that the ingestion of C. longa
increased postprandial serum insulin levels, but did not
affect plasma glucose levels or GI in healthy subjects.
The results indicate that C. longa may have an effect on
insulin secretion.
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